Browse the evidence

GLP-1 receptor agonists provide additive kidney benefits when used in combination with SGLT2 inhibitors, addressing residual cardiorenal risk.

If you are already taking an SGLT2 inhibitor for your kidney and heart health, ask your doctor if adding a GLP-1 receptor agonist could provide additional protection. These medications work through different mechanisms and can offer additive benefits, especially if you still have residual risk factors like high blood pressure or albuminuria.

Incretin therapies (semaglutide, tirzepatide) achieve MASH resolution and fibrosis improvement primarily through substantial, dose-dependent weight loss.

Semaglutide (2.4 mg weekly) and tirzepatide are weekly injections that reduce liver fat and inflammation by driving significant weight loss. They are highly effective for MASH resolution.

Emerging weight-lowering drugs (GLP-1/GIP/Glucagon agonists, amylin analogues, activin receptor antagonists) reduce cardiovascular risk factors (blood pressure, lipids, inflammation) and major adverse cardiovascular events (MACE) in obese patients, with some effects being independent of weight loss.

If you are obese and have cardiovascular risk factors, emerging drugs like semaglutide and tirzepatide offer significant benefits beyond just weight loss, including reduced risk of heart attacks and strokes. These benefits may come from direct effects on blood vessels and inflammation, not just weight loss. While side effects like nausea are common, they can often be managed. Oral options are becoming available, reducing the need for injections. These drugs are most effective when combined with lifestyle changes, but they can provide substantial help where lifestyle alone has failed.

Combining gut hormone analog medications (e.g., GLP-1/GIP agonists) with naltrexone-bupropion extended-release (NB-ER) provides a mechanistic rationale for improved weight loss in patients who fail to achieve goals with monotherapy, by targeting distinct satiety and reward pathways.

If you are taking a GLP-1 medication (like semaglutide or tirzepatide) and hitting a plateau or struggling with food cravings despite following the dose, ask your doctor about adding NB-ER (naltrexone-bupropion). This combination targets both physical fullness and the brain's reward system, which may help you lose more weight than the single medication alone.

Gut hormone analog medications (liraglutide, semaglutide, tirzepatide) reduce energy intake and alter food preferences primarily through delayed gastric emptying and hypothalamic/brainstem satiety signaling, rather than direct effects on reward centers.

GLP-1 medications like semaglutide work mainly by slowing digestion and signaling fullness to the brain, leading to significant weight loss (up to 21% for tirzepatide). While they may help with cravings, this is likely a secondary effect of weight loss rather than a direct 'craving blocker' action.

NB-ER (naltrexone-bupropion extended-release) reduces food cravings and improves control over eating by acting on central hypothalamic and mesolimbic dopaminergic systems, distinct from the peripheral effects of gut hormone analogs.

NB-ER helps with weight loss by targeting the brain's reward system to reduce cravings and improve self-control, rather than just slowing digestion. It typically leads to 6-12% weight loss over a year, depending on whether you have diabetes.

Tirzepatide is associated with significantly greater lean body mass (LBM) loss compared to semaglutide during routine care, with excess relative LBM losses of 1.1% to 2.0% at 3, 6, 9, and 12 months respectively.

If you are taking tirzepatide, expect to lose more lean muscle mass than if you were taking semaglutide for the same amount of weight loss. This effect increases with higher doses and longer duration. To counteract this, prioritize resistance training and adequate protein intake, and monitor your body composition, not just scale weight.

Incretin therapies reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with T2DM and/or established cardiovascular disease, independent of glycemic control.

If you have heart disease or high risk, these drugs offer significant protection against heart attacks and death, separate from weight loss. This benefit is a key factor in their clinical value and reimbursement decisions.

Next-generation incretin-based therapies (GLP-1 and GLP-1/GIP receptor agonists) significantly reduce systolic blood pressure, with the majority of this effect mediated by weight loss, though direct tissue-specific mechanisms also contribute.

If you have high blood pressure and obesity or type 2 diabetes, GLP-1 based medications like semaglutide or tirzepatide can significantly lower your blood pressure. Most of this benefit comes from the weight loss these drugs cause, but they also have direct positive effects on your blood vessels and kidneys. While they are more expensive than standard blood pressure pills, they offer broader cardiovascular protection. Discuss with your doctor if you are a candidate, especially if you have resistant hypertension or high cardiovascular risk.

GLP-1/GIP receptor co-agonists may provide cardiovascular protection and slow the decline of kidney function in individuals with type 2 diabetes.

GLP-1/GIP receptor co-agonists may be considered for patients with type 2 diabetes at risk for cardiovascular and kidney issues.

Tirzepatide may provide additional benefits beyond glycemic control for T2DM patients.

Tirzepatide may be beneficial for T2DM patients in ways beyond just lowering blood sugar.

GLP-1 agonists may provide additional benefits beyond weight loss and diabetes management.

Providers should explore the broader implications of GLP-1 agonists for patients with various conditions.

Combining GLP-1 RAs with EBTs may yield synergistic effects.

Practitioners may explore combination therapies for enhanced weight loss outcomes.

Liraglutide was well-tolerated, with benefits experienced by over 90% of patients.

Liraglutide can be considered a safe option for obesity management in clinical practice.

Individuals without diabetes were more likely to achieve ≥10% weight loss compared to individuals with T2D (21.4% vs. 0%).

Practitioners may consider the likelihood of achieving significant weight loss when prescribing tirzepatide based on diabetes status.

Adhering to a hypercaloric, high-protein plant-based diet during resistance training preserves insulin sensitivity (HOMA-IR) and prevents the rise in fasting serum insulin seen with an isoenergetic, isonitrogenous omnivorous diet.

If you are eating enough protein (around 2g per kg of body weight) and training hard, choosing a plant-based diet rich in mycoprotein (like Quorn) can help keep your insulin sensitivity stable. You don't need to worry about the metabolic downsides often associated with high-protein diets, as long as you match the calories and protein of an omnivorous diet.

Tirzepatide improves cardiovascular risk factors, including blood pressure, lipid profiles, and liver fat content, in patients with type 2 diabetes, without increasing the risk of major adverse cardiovascular events in high-risk patients.

Tirzepatide not only lowers blood sugar and helps with weight loss but also improves other heart health markers like blood pressure, cholesterol, and liver fat. For patients with type 2 diabetes who are at high risk for heart problems, tirzepatide has not been shown to increase the risk of major cardiovascular events. This makes it a valuable option for comprehensive diabetes management, addressing both metabolic and cardiovascular health.

Sleep duration has a non-linear (L-shaped or U-shaped) relationship with MACE subtypes, with optimal benefits for heart failure but potential risks for myocardial infarction and stroke at longer durations.

While getting enough sleep (8-9.5 hours) is generally beneficial for heart health, be aware that the relationship between sleep duration and specific heart conditions varies. For heart failure, more sleep is linearly beneficial. For heart attacks and strokes, very long sleep durations might not offer additional benefits and could potentially be linked to other risks. Aim for the 8-9.5 hour range as a general guideline.

In males with type 2 diabetes, higher baseline endogenous total testosterone and lower estradiol levels significantly enhance the reduction of triglycerides achieved through intensive lifestyle intervention.

If you are a man with type 2 diabetes, your baseline testosterone and estradiol levels may dictate how effectively your diet and exercise efforts lower triglycerides. Men with higher testosterone and lower estradiol tend to see bigger improvements in triglycerides from lifestyle changes. This suggests that knowing your hormone profile could help tailor your lifestyle prescription for better lipid outcomes.

In females with type 2 diabetes, higher baseline sex hormone-binding globulin (SHBG) significantly enhances the reduction of LDL cholesterol achieved through intensive lifestyle intervention.

If you are a postmenopausal woman with type 2 diabetes, your baseline SHBG levels may dictate how effectively your diet and exercise efforts lower LDL cholesterol. Women with higher SHBG tend to see bigger improvements in LDL-C from lifestyle changes. This suggests that knowing your hormone profile could help tailor your lifestyle prescription for better lipid outcomes.

Higher baseline total testosterone predicts greater long-term weight loss and waist circumference reduction in both males and females with type 2 diabetes undergoing intensive lifestyle intervention.

If you have type 2 diabetes, your baseline testosterone levels may dictate how effectively your diet and exercise efforts lead to weight loss and waist circumference reduction. Both men and women with higher testosterone tend to see bigger improvements in weight and waist size from lifestyle changes. This suggests that knowing your hormone profile could help tailor your lifestyle prescription for better weight outcomes.

Metabolic bariatric surgery leads to sustained HbA1c reduction, whereas non-surgical management is associated with HbA1c increase in patients with type 2 diabetes.

For patients with severe obesity and type 2 diabetes, metabolic bariatric surgery offers significantly better long-term weight loss and blood sugar control than non-surgical management. While surgery is not for everyone, those who undergo it maintain much greater weight loss (22% vs 8.6%) and better glycemic control over five years. If surgery is not an option, intensive lifestyle modification and pharmacotherapy are critical alternatives to mitigate health risks.

Achieving comprehensive metabolic control (simultaneous HbA1c, LDL-C, and blood pressure targets) significantly reduces the risk of cardiovascular and microvascular complications in diabetic patients.

For diabetic patients, managing blood sugar, blood pressure, and cholesterol together is critical. Missing any one target leaves you at higher risk for heart and kidney damage. Work with your doctor to hit all three goals simultaneously, not just one.

Probiotic and synbiotic supplementation improves glycemic control, lipid profiles, and reduces inflammation in patients with type 2 diabetes and obesity, with strain-specific effects.

Taking specific probiotic or synbiotic supplements daily can modestly improve blood sugar and cholesterol levels in people with diabetes or obesity. Choose strains with clinical evidence (like Lactobacillus acidophilus or Bifidobacterium lactis) and take them consistently for at least 12 weeks.